ABSTRACT
OBJECTIVES: To assess the effect of protease inhibitor (PI)-based dual therapy on CD4/CD8 ratio during the first year of therapy in antiretroviral therapy (ART)-naïve patients using data from randomized controlled clinical trials. METHODS: We pooled data from the GARDEL and ANDES studies, both randomized controlled clinical trials that recruited ART-naïve people living with HIV and randomly assigned them to receive PI-based dual therapy (DT) or triple therapy (TT) aiming to compare viral efficacy. We compared median CD4/CD8 ratios and the proportion of patients with CD4/CD8 ratio > 1 at 48 weeks after ART initiation in both treatment arms using the Mann-Whitney U-test and the χ2 test. We performed subgroup analysis for patients > 50 years old, with baseline CD4 counts ≤ 200 cells/µL, viral load > 100 000 HIV RNA copies/mL, and ritonavir-boosted lopinavir-based therapy. RESULTS: We analysed data from 571 patients: 292 on DT and 279 on TT. No differences were observed in CD4/CD8 ratio (0.632 vs. 0.617, P = 0.729) or in the proportion of patients with CD4/CD8 ratio > 1 (17.9% vs. 19.3%, P = 0.678) 48 weeks after ART initiation. Subgroup analysis showed no further differences. CONCLUSION: The impact of PI-based DT regimens on the CD4/CD8 ratio during the first year of treatment for ART-naïve patients is similar to that of TT.
Subject(s)
Anti-HIV Agents , HIV Infections , HIV Protease Inhibitors , HIV-1 , CD4 Lymphocyte Count , CD8-Positive T-Lymphocytes , HIV Infections/drug therapy , Humans , Lamivudine/therapeutic use , Middle Aged , Reverse Transcriptase Inhibitors , Ritonavir/pharmacology , Ritonavir/therapeutic use , Viral LoadABSTRACT
BACKGROUND: The incidence of sexually transmitted infections (STIs), particularly syphilis, is high and continues to rise among some populations, especially among men who have sex with men (MSM). Furthermore, a higher incidence of STIs has been reported in HIV-positive than in HIV-negative MSM. OBJECTIVE: To determine the incidence of syphilis in a cohort of men with HIV in Buenos Aires city. METHODS: Retrospective cohort study. We examined the records and visits made by men with HIV aged >18â years in our institution during a 1-year period. Venereal Disease Reference Laboratory (VDRL) results for all the men in our cohort during the study period were analysed. We considered a case of syphilis as incident if a person had a VDRL result of ≥16 DILS, provided that this was increased at least fourfold compared with a previous determination. All VDRL results ≤8 were investigated, and analysed together with the medical records, to determine if they were new cases. RESULTS: We analysed the VDRL results and the clinical records of 1150 men followed up in our centre during the study period. Mean age was 40.9â years. According to the definition used, we registered 171 new cases of syphilis-that is, an incidence of 14.9/100 patients/year (95% CI 12.9 to 17.0). No significant differences in incidence according to age group were found, but there was a trend towards a lower incidence in older men. Ten men had two new episodes during the study. CONCLUSIONS: The incidence of syphilis in this cohort of men with HIV (predominantly MSM) was very high. In addition to maintaining high surveillance for early diagnosis and treatment, it is necessary to implement newer and more effective measures to prevent syphilis and other STIs in this population.
Subject(s)
HIV Infections/complications , Homosexuality, Male , Syphilis/complications , Syphilis/epidemiology , Adolescent , Adult , Argentina/epidemiology , Cohort Studies , HIV Infections/epidemiology , HIV Infections/virology , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Sexually Transmitted Diseases/epidemiology , Syphilis/diagnosis , Syphilis/prevention & control , Young AdultABSTRACT
BACKGROUND: Community-acquired pneumonia (CAP) severity scores can identify patients at low risk for mortality who may be suitable for ambulatory care. Here, we follow the clinical course of hospitalized patients with CAP due to 2009 H1N1 influenza. OBJECTIVE: To evaluate the role of CAP severity scores as predictors of mortality. METHODS: This was a secondary data analysis of patients hospitalized with CAP due to 2009 H1N1 influenza confirmed by reverse transcriptase polymerase chain reaction enrolled in the CAPO (Community-Acquired Pneumonia Organization) international cohort study. CAP severity scores PSI (Pneumonia Severity Index), CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥ 65 years) and CRB-65 (confusion, respiratory rate, blood pressure, age ≥ 65 years) were calculated. Actual and predicted mortality rates were compared. A total of 37 predictor variables were evaluated to define those associated with mortality. RESULTS: Data from 250 patients with CAP due to 2009 H1N1 influenza were analyzed. Patients with low predicted mortality rates (0-1.5%) had actual mortality rates ranging from 2.6% to 17.5%. Obesity and wheezing were the only novel variables associated with mortality. CONCLUSIONS: The decision to hospitalize a patient with CAP due to 2009 H1N1 influenza should not be based on current CAP severity scores, as they underestimate mortality rates in a significant number of patients. Patients with obesity or wheezing should be considered at an increased risk for mortality.
Subject(s)
Community-Acquired Infections/mortality , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/mortality , Pneumonia, Viral/mortality , Adult , Aged , Cohort Studies , Community-Acquired Infections/physiopathology , Community-Acquired Infections/virology , Female , Forecasting , Hospitalization , Humans , Influenza, Human/complications , Influenza, Human/physiopathology , Male , Middle Aged , Obesity/complications , Pneumonia, Viral/physiopathology , Pneumonia, Viral/virology , Respiratory Sounds/physiopathology , Risk Factors , Severity of Illness IndexABSTRACT
OBJECTIVE: To evaluate the prevalence of and the associated factors for metabolic syndrome (MS) among Latin American HIV-infected patients receiving antiretroviral therapy (ART) using baseline data from the RAPID II study. METHODS: A longitudinal study to evaluate the metabolic profile, cardiovascular disease (CVD) risk and associated treatment practices to reduce this risk has been conducted in seven Latin American countries (the RAPID II study). Adult HIV patients with at least six months of RT were enrolled. MS was defined following ATP-III criteria. Demographic and anthropometric data, serum biochemical and clinical parameters were compared in patients with and without MS using bivariate and multivariate analysis. RESULTS: A total of 4,010 patients were enrolled, 2,963 (74%) were males. Mean age (SD) was 41.9 (10.0) years. The prevalence of MS was 20.2%. Females had higher prevalence of MS than males (22.7% vs. 19.4%, p = 0.02). MS was driven by high triglycerides, low HDL-cholesterol and high blood pressure (HBP). Patients with MS had higher 10 year CVD risk: 22.2% vs. 7.4%, p < 0.001. Age (OR: 1.05 per year), female gender (OR: 1.29), family history of CVD (OR: 1.28), CD4 cell count (OR: 1.09 per 100 cell increase), and protease inhibitor based-ART (OR: 1.33) correlated with MS in the multivariate analysis. CONCLUSIONS: Prevalence of MS in this setting was similar to that reported from developed countries. MS was driven by high triglycerides, low-HDL and HBP, and it was associated with higher risk of CVD. Traditional risk factors, female gender, immune reconstitution, and protease inhibitor based-ART correlated with MS.
Subject(s)
Anti-HIV Agents/adverse effects , HIV Infections/drug therapy , Metabolic Syndrome/chemically induced , Adolescent , Adult , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Cross-Sectional Studies , Female , Humans , Latin America/epidemiology , Longitudinal Studies , Male , Metabolic Syndrome/epidemiology , Middle Aged , Prevalence , Viral Load , Young AdultABSTRACT
BACKGROUND: This study compared the investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate (MenACWY-D) meningococcal vaccines. METHODS: In this phase III multicenter study, 2505 adults (aged 19-55 years) were randomized to receive either MenACWY-CRM or MenACWY-D, and 326 adults (aged 56-65 years) were randomized to receive either MenACWY-CRM or MPSV4. Sera obtained pre-vaccination and at 1-month post-vaccination were tested for serogroup-specific serum bactericidal activity using human complement (hSBA) for immunogenicity non-inferiority and superiority analyses. RESULTS: The vaccines in all groups were well tolerated. In the 19-55 years age group, post-vaccination geometric mean titers (GMTs) were consistently higher for MenACWY-CRM than for MenACWY-D for all four serogroups. MenACWY-CRM was non-inferior to MenACWY-D for all serogroups, and superior for serogroup Y. In the 56-65 years age group, post-vaccination GMTs were 1.2- to 5.4-fold higher for MenACWY-CRM than for MPSV4 for the four serogroups. CONCLUSIONS: MenACWY-CRM is well tolerated and immunogenic in adults aged 19-65 years, with at least non-inferior immunogenicity compared with the currently licensed meningococcal vaccines.
Subject(s)
Meningococcal Vaccines/adverse effects , Meningococcal Vaccines/immunology , Vaccines, Conjugate/adverse effects , Vaccines, Conjugate/immunology , Adult , Argentina , Colombia , Female , Humans , Male , Middle AgedABSTRACT
OBJECTIVE: To evaluate the prevalence of and the associated factors for metabolic syndrome (MS) among Latin American HIV-infected patients receiving antiretroviral therapy (ART) using baseline data from the RAPID II study. METHODS: A longitudinal study to evaluate the metabolic profile, cardiovascular disease (CVD) risk and associated treatment practices to reduce this risk has been conducted in seven Latin American countries (the RAPID II study). Adult HIV patients with at least six months of RT were enrolled. MS was defined following ATP-III criteria. Demographic and anthropometric data, serum biochemical and clinical parameters were compared in patients with and without MS using bivariate and multivariate analysis. RESULTS: A total of 4,010 patients were enrolled, 2,963 (74 percent) were males. Mean age (SD) was 41.9 (10.0) years. The prevalence of MS was 20.2 percent. Females had higher prevalence of MS than males (22.7 percent vs. 19.4 percent, p = 0.02). MS was driven by high triglycerides, low HDL-cholesterol and high blood pressure (HBP). Patients with MS had higher 10year CVD risk: 22.2 percent vs. 7.4 percent, p < 0.001. Age (OR: 1.05 per year), female gender (OR: 1.29), family history of CVD (OR: 1.28), CD4 cell count (OR: 1.09 per 100 cell increase), and protease inhibitor based-ART (OR: 1.33) correlated with MS in the multivariate analysis. CONCLUSIONS: Prevalence of MS in this setting was similar to that reported from developed countries. MS was driven by high triglycerides, low-HDL and HBP, and it was associated with higher risk of CVD. Traditional risk factors, female gender, immune reconstitution, and protease inhibitor based-ART correlated with MS.
Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Anti-HIV Agents/adverse effects , HIV Infections/drug therapy , Metabolic Syndrome/chemically induced , Anti-HIV Agents/therapeutic use , Cross-Sectional Studies , Longitudinal Studies , Latin America/epidemiology , Metabolic Syndrome/epidemiology , Prevalence , Viral Load , Young AdultABSTRACT
Objetivo: Evaluar el desarrollo de la investigación y la publicación científica de los nutricionistas argentinos a través del análisis histórico y bibliométrico de la revista Diaeta. Método: Diseño descriptivo transversal. Todos los números de la revista Diaeta desde el comienzo de su edición en 1981 hasta fines de 2008 fueron incluidos. Se obtuvo una muestra de 63 ejemplares mediante muestreo estratificado por cada año. Resultados: Se observó un aumento en el porcentaje de Artículos Originales y el aumento en otras áreas temáticas diferentes de la tradicional de Dietoterapia. El promedio del número de autores por artículo científico, fue de tres por Artículo Original y dos autores por Trabajo de Actualización y/o Revisión. Las citas bibliográficas fueron en su mayoría en idioma inglés, en segundo término en español. Las profesiones de los autores más productivos, además de los Licenciados en Nutrición fueron; médicos, químicos, e ingenieros. Conclusiones: La revista DIAETA ha mostrado en pocos años un importante progreso acompañando el desarrollo de la investigación de los nutricionistas del país.
Subject(s)
Bibliometrics , Periodical , ResearchABSTRACT
Objetivo: Evaluar el desarrollo de la investigación y la publicación científica de los nutricionistas argentinos a través del análisis histórico y bibliométrico de la revista Diaeta. Método: Diseño descriptivo transversal. Todos los números de la revista Diaeta desde el comienzo de su edición en 1981 hasta fines de 2008 fueron incluidos. Se obtuvo una muestra de 63 ejemplares mediante muestreo estratificado por cada año. Resultados: Se observó un aumento en el porcentaje de Artículos Originales y el aumento en otras áreas temáticas diferentes de la tradicional de Dietoterapia. El promedio del número de autores por artículo científico, fue de tres por Artículo Original y dos autores por Trabajo de Actualización y/o Revisión. Las citas bibliográficas fueron en su mayoría en idioma inglés, en segundo término en español. Las profesiones de los autores más productivos, además de los Licenciados en Nutrición fueron; médicos, químicos, e ingenieros. Conclusiones: La revista DIAETA ha mostrado en pocos años un importante progreso acompañando el desarrollo de la investigación de los nutricionistas del país.(AU)
Subject(s)
Bibliometrics , Periodical , ResearchABSTRACT
Although the presence of neutropenia may predispose cancer patients to develop community-acquired pneumonia, the role of neutropenia on their outcomes has not been investigated. The purpose of the present study was to compare clinical outcomes of cancer community-acquired pneumonia patients with and without neutropenia. Patients with cancer, identified in the Community-Acquired Pneumonia Organization database, were divided into two groups according to the type of cancer and the presence of neutropenia: patients with solid cancer without neutropenia versus those with functional or absolute neutropenia. Among the 3,106 community-acquired pneumonia patients enrolled, 135 had cancer without neutropenia and 75 had cancer with neutropenia. No significant difference was found between patients with and without neutropenia regarding mean time to clinical stability (5.4+/-2.7 versus 4.9+/-2.7 days, respectively), mean length of hospital stay (9.2+/-7.7 versus 9.9+/-9.6 days) and in-hospital mortality (18 versus 15%, respectively). Using a multiple logistic regression model, neutropenia was not associated with mortality in cancer patients when adjusting for significant covariates (odds ratio 1.30). Lack of neutropenia, during the initial evaluation of a cancer community-acquired pneumonia patient, should not be considered an indicator of better clinical outcome.
Subject(s)
Neoplasms/complications , Neutropenia/complications , Pneumonia/complications , Pneumonia/mortality , Aged , Aged, 80 and over , Cohort Studies , Community-Acquired Infections/complications , Community-Acquired Infections/mortality , Community-Acquired Infections/therapy , Databases, Factual , Female , Humans , Length of Stay , Male , Middle Aged , Neoplasms/mortality , Neoplasms/therapy , Neutropenia/mortality , Neutropenia/therapy , Pneumonia/therapy , Retrospective Studies , Risk Factors , Survival Rate , Treatment OutcomeABSTRACT
Therapy of uncomplicated urinary tract infection (UTI) is based on knowledge of in vitro susceptibility profiles of uropathogens in the geographic region. Microbiological surveillance systems, which lack epidemiological and clinical data to differentiate between complicated and uncomplicated UTI may incorrectly estimate rates of resistance in the community. We determined the susceptibility profile of bacteria isolated from a random sample of 124 adult outpatients with diagnosis of uncomplicated UTI and we compared it with all outpatient urine specimens collected by the same participant laboratories during the same period. Escherichia coli was the most frequently isolated uropathogen in patients with uncomplicated UTI, and its rate of resistance to different antimicrobials was lower than overall resistance rates to E. coli reported by the participating laboratories during the same period. Resistance to cotrimoxazole was significantly lower. These results suggest that surveillance systems without clinical and epidemiological data may incorrectly gauge uropathogen resistance in the community.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Urinary Tract Infections/drug therapy , Adult , Drug Resistance, Bacterial , Humans , Microbial Sensitivity Tests , Prospective Studies , Urinary Tract Infections/microbiologyABSTRACT
Patients with infective endocarditis often face lengthy hospitalization for parenteral antibiotic therapy. Efforts to reduce medical costs have led to consideration of outpatient parenteral antibiotic treatment (OPAT) for these patients. However, concerns about outpatient management of complications, particularly congestive heart failure and emboli, exist. In Argentina, carefully selected patients with infective endocarditis, representing a low-risk population, have been successfully treated with OPAT. A retrospective analysis was conducted of 48 such patients. Three delivery models were used: at home with medications given by the visiting nurse, at infusion center, or at home with medications self-administered. Ten patients received OPAT only; 38 were initially hospitalized, then transferred to an OPAT program. Twenty-nine patients had streptococcal disease, 37 out of 48 patients were treated with ceftriaxone. Clinical and microbiologic cure was achieved in all patients. Three patients developed heart failure, 2 prior to starting antibiotic therapy. Four developed emboli, all prior to starting antibiotics. Surgery was required in 5 patients: 2 were treated with OPAT postoperatively and 3 had surgery after antibiotic therapy was completed. OPAT for infective endocarditis is safe in well selected patients.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Endocarditis, Bacterial/drug therapy , Argentina , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/pathology , Heart Failure/etiology , Humans , Infusions, Parenteral , Outpatients , Retrospective Studies , Thromboembolism/etiology , Treatment OutcomeABSTRACT
A total of 73 patients with baseline CD4+ cell counts >/=350 cells/mm3 who were receiving combination antiretroviral therapy (ART) were randomized to receive subcutaneous interleukin-2 (IL-2; n=36) in addition to ART or to continue ART alone (n=37). Subcutaneous IL-2 was delivered at 1 of 3 doses (1.5 million international units ¿MIU, 4.5 MIU, and 7.5 MIU per dose) by twice-daily injection for 5 consecutive days every 8 weeks. After 24 weeks, the time-weighted mean change from baseline CD4+ cell count was 210 cells/mm3 for recipients of subcutaneous IL-2, compared with 29 cells/mm3 for recipients of ART alone (P<.001). There were no significant differences between treatment groups for measures of plasma human immunodeficiency virus RNA (P=.851). Subcutaneous IL-2 delivered at doses of 4.5 MIU and 7.5 MIU resulted in significant increases in CD4+ cell count (P=.006 and P<.001, respectively), compared with that seen in control patients. These changes were not significant in the 1.5 MIU dose group compared with that in the control patients (P=.105). Side effects that occurred from subcutaneous IL-2 administration were generally low grade, of short duration, and readily managed in an outpatient environment.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Interleukin-2/therapeutic use , Adult , Anti-HIV Agents/adverse effects , CD4 Lymphocyte Count , CD8-Positive T-Lymphocytes/immunology , Didanosine/therapeutic use , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Female , HIV Infections/immunology , Humans , Indinavir/therapeutic use , Injections, Subcutaneous , Interleukin-2/administration & dosage , Interleukin-2/adverse effects , Lamivudine/therapeutic use , Lymphocyte Count , Male , Nelfinavir/administration & dosage , Nevirapine/administration & dosage , RNA, Viral/blood , Ritonavir/administration & dosage , Saquinavir/administration & dosage , Stavudine/therapeutic use , Zalcitabine/administration & dosage , Zidovudine/administration & dosageABSTRACT
To evaluate the efficacy of ganciclovir, foscarnet, or the combination of both for the treatment of cytomegalovirus polyradiculomyelopathy (CMV-PRAM), we reviewed the records of seven patients with AIDS, diagnosed with CMV-PRAM. Muscle strength was graded according to the Medical Research Council (MRC) scale. Response to treatment was also classified according to MRC scale, based on the degree of improvement in muscle strength. Six of 7 patients had a good response to treatment, reaching the MRC scale of 4, or improving at least 3 degrees in the same scale. CMV-PRAM may be treated with ganciclovir alone or in combination with foscarnet.